DNA concentrations in BAL fluid of cystic fibrosis patients with early lung disease: Influence of treatment with dornase alpha

Pediatric Pulmonology

Volumn 39, Issue 1, 2005, Pages 1-4

  Ratjen, F ^a   Paul, K ^b   Van Koningsbruggen, S ^c   Breitenstein, S ^a   Rietschel, E ^c   Nikolaizik, W ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c HUMBOLDT UNIVERSITY   (Germany)

Author keywords

Bronchoalveolar lavage; Cystic fibrosis; Dornase alpha

Indexed keywords

DORNASE ALFA; RECOMBINANT DNA;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CORRELATION ANALYSIS; CYSTIC FIBROSIS; DISEASE EXACERBATION; DNA DETERMINATION; DRUG EFFICACY; FEMALE; HUMAN; INFANT; LOWER RESPIRATORY TRACT; LUNG CLEARANCE; LUNG DISEASE; LUNG LAVAGE; MALE; NEUTROPHIL; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; SPUTUM;

ADOLESCENT; ADULT; BRONCHOALVEOLAR LAVAGE FLUID; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; DEOXYRIBONUCLEASE I; DNA; FEMALE; HUMANS; INFLAMMATION; MALE; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 10344264976     PISSN: 87556863     EISSN: None     Source Type: Journal    
DOI: 10.1002/ppul.20134     Document Type: Article

References (22)

1. Ratjen F, Döring G. Cystic fibrosis. Lancet 2003;361:681-689.
2. Konstan MW, Berger M. Current understanding of the inflammatory process in cystic fibrosis: onset and etiology. Pediatr Pulmonol 1997;24:137-114.
3. Shak S, Capon DJ, Helms R, Masters SA, Baker CL. Recombinant human DNase reduced the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci USA 1990;87:9188-9192.
4. Fuchs HJ, Borowith DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosenstein BJ, Smith AL, Wohl ME. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994;331:637-642.
5. Hodson ME, Shah PL. RhDNase trials in cystic fibrosis. Eur Respir J 1995;8:1786-1791.
6. Kearney CE, Wallis CE. Deoxyribonuclease for cystic fibrosis. Cochrane Database Syst Rev 2000;2:CD001127.
7. Quan JM, Tiddens HA, Sy JP, et al. The Pulmozyme Early Intervention Trial Study Group. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr 2001;139:813-820.
8. Paul K, Rietschel E, Ballmann M, Griese M, Worlitzsch D, Shute J, Chen C, Schink T, Döring G, van Koningsbruggen S, Wahn U, Ratjen F, for the BEAT Study Group. Effect of dornase alpha on airway inflammation in cystic fibrosis. Am J Respir Care Med 2004;169:719-725.
9. Ratjen F, Rietschel E, Griese M, Ballmann M, Kleinau I, Döring G, Reinhardt D, Paul K. Fractional analysis of bronchoalveolar lavage fluid cytology in cystic fibrosis patients with normal lung function. Bronchoalveolar Lavage for the Evaluation of Anti-Inflammatory Treatment (BEAT) Study Group. Eur Respir J 2000;15:141-145.
10. Ratjen F, Bredendiek M, Brendel M, Meitzer J, Costabel U. Differential cytology for bronchoalveolar lavage fluid in normal children. Eur Respir J 1994;7:1865-1870.
11. Kirchner KK, Wagener JS, Khan TZ, Copenhaver SC, Accurso FJ. Increased DNA levels in bronchoalveolar lavage fluid obtained from infants with cystic fibrosis. Am J Respir Crit Care Med 1996;154:1426-1429.
12. Griese M, App EM, Derouix A, Burkert A, Schams A. Recombinant human DNase (rhDNase) influences phospholipid composition, surface activity, rheology and consecutively clearance indices of cystic fibrosis sputum. Pulm Pharmacol Ther 1997;10:21-27.
13. Brandt T, Breitenstein S, von der Hardt H, Tümmler B. DNA concentration and length in sputum of patients with cystic fibrosis during inhalation with recombinant human DNase. Thorax 1995;50:880-882.
14. Ratjen F, Tümmler B. Comparison of the in vitro and in vivo response to inhaled DNase in patients with cystic fibrosis. Thorax 1999;54:91.
15. Konstan MW, Hilliard KA, Norvell TM, et al. Bronchoalveolar lavage findings in cystic fibrosis patients with stable, clinically mild lung disease suggest ongoing infection and inflammation. Am J Respir Crit Care Med 1994;150:448-454.
16. Khan TZ, Wagener JS, Bost T, Martinez J, Accurso JF, Riches DWH. Early pulmonary inflammation in infants with cystic fibrosis. Am J Respir Crit Care Med 1995;151:1075-1082.
17. Armstrong DS, Grimwood K, Carzino R, et al. Lower respiratory infection and inflammation in newly diagnosed cystic fibrosis. Br Med J [Clin Res] 1995;310:1571-1572.
18. Dakin CJ, Numa AH, Wang H, Morton JR, Vertzyas CC, Henry RL. Inflammation, infection, and pulmonary function in infants and young children with cystic fibrosis. Am J Respir Crit Care Med 2002;165:904-910.
19. Eigen H, Rosenstein BJ, Fitzsimmons S, et al. A multicenter study of alternate-day prednisone therapy in patients with cystic fibrosis. J Pediatr 1995;126:515-523.
20. Cheng K, Ashby D, Smyth R. Oral steroids for cystic fibrosis. Cochrane Database Syst Rev 2000;2:CD000407.
21. Konstan MW, Byard PJ, Hoppel CL, et al. Effect of high-dose ibuprofen in patients with cystic fibrosis. N Engl J Med 1995;332:848-854.
22. Dezateux C, Crighton A. Oral non-steroidal anti-inflammatory drug therapy for cystic fibrosis. Cochrane Database Syst Rev 2000;2:CD001505.